Myriad Genetics, Inc. Forecast, price target & analysts
Myriad Genetics, Inc. Target price 2025 - Analyst rating & recommendation
Myriad Genetics, Inc. Classifications & Recommendation:
Myriad Genetics, Inc. Price Target
| Target Price | $7.14 |
| Price | $5.25 |
| Potential |
36.00%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Myriad Genetics, Inc. 2026 .
The average Myriad Genetics, Inc. target price is $7.14.
This is
36.00%
register free of charge
$18.90
260.00%
register free of charge
$4.04
23.05%
register free of charge
|
|
| A rating was issued by 22 analysts: 4 Analysts recommend Myriad Genetics, Inc. to buy, 11 to hold and 7 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Myriad Genetics, Inc. stock has an average upside potential 2026 of
36.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 837.60 | 826.61 |
| 11.21% | 1.31% | |
| EBITDA Margin | -3.20% | 2.47% |
| 67.87% | 177.20% |
18 Analysts have issued a sales forecast Myriad Genetics, Inc. 2025 . The average Myriad Genetics, Inc. sales estimate is
This results in the following potential growth metrics:
16 Analysts have issued an Myriad Genetics, Inc. EBITDA forecast 2025. The average Myriad Genetics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.41 | -0.01 |
| 55.66% | 99.29% | |
| P/E | negative |
18 Analysts have issued a Myriad Genetics, Inc. forecast for earnings per share. The average Myriad Genetics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Myriad Genetics, Inc....
Current Myriad Genetics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Scotiabank |
Locked
➜
Locked
|
Locked | May 21 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | May 15 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | May 07 2025 |
| UBS |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Scotiabank:
Locked
➜
Locked
|
May 21 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
